Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

Eli Lilly launches Mounjaro KwikPen in India, expanding weight-loss drug options and intensifying competition with Novo Nordisk.

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with ...

Also, in 2026, semaglutide's patent expires in China which is expected to bring a flood of cheaper generic versions, and will likely put pressure on Novo and Lilly to lower the prices of their ...

(Reuters) -India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with ...

3. Justifying its valuation with its outlook Eli Lilly's valuation might be a significant stumbling block for some investors. If the stock fails to meet the market's lofty expectations, its shares ...

Lilly’s tirzepatide shortage ended first, with the FDA officially declaring the situation resolved early last October. The regulator erased Novo’s semaglutide from its shortage list in February.

SYRACUSE — At last year’s inaugural “Famous Hoosiers” program Richard Gunderman made a moving and very well received presentation about Hoosier legend John Wooden.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock.